Antibodies
27 February 2012
FDA approves protocol amendment needed to conduct the final analysis of the pivotal RENCAREX Phase III trial22 February 2012
UCB announces start of C-EARLY™ study for Cimzia (certolizumab pegol) in rheumatoid arthritis20 February 2012
Positive One Year results From Phase 3 Study in Central Retinal Vein Occlusion of VEGF Trap-Eye8 February 2012
Amgen to Discuss Application for New Use of XGEVA® (denosumab) at FDA Oncologic Drugs Advisory Committee Meeting7 February 2012
FDA Grants Genentech’s Pertuzumab Priority Review for Previously Untreated HER2-Positive Metastatic Breast Cancer2 February 2012
Compugen Cancer Target Results Demonstrate Significant Potential for Cancer Immunotherapy30 January 2012
biOasis Advances its Herceptin(R) BT2111 Program29 January 2012
Lpath Temporarily Suspends Dosing of iSONEP in Clinical Trials Due to cGMP Compliance Issues at Contract Fill/Finish Source29 January 2012
Seattle Genetics and Millennium Report Data from Phase I Trial of ADCETRIS in Front-line Mature T-Cell Lymphomas29 January 2012
Seattle Genetics Announces Data from ADCETRIS in Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma26 January 2012
ASCEND Study to Evaluate the Effectiveness of TYSABRI® (natalizumab) as a Treatment for Secondary-Progressive Multiple Sclerosis24 January 2012
Baxter to Initiate Second Phase III Trial Studying GAMMAGARD LIQUID (IGIV) for the Treatment of Alzheimer’s Disease21 January 2012
Remicade® (Infliximab) Receives Positive Opinion From CHMP In Europe for Treatment of Ulcerative Colitis in Pediatric Patients21 January 2012
FDA Updates TYSABRI® (natalizumab) Label to Include Anti-JC Virus Antibody Status as a PML Risk Factor13 January 2012
Genentech Announces First Milestone Payment to Device-Maker ForSight VISION4, Inc. in Development of Sustained Delivery Lucentis12 January 2012
Three Adimab Antibodies Enter Human Clinical Trials9 January 2012
Biocon Announces Positive Efficacy Data with its Novel Monoclonal Antibody Itolizumab in a Pivotal Psoriasis StudyNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports